Skip to content
Search

Latest Stories

Whitworth Chemists puts six high-dispensing Blackpool pharmacies up for sale

Whitworth Chemists puts six high-dispensing Blackpool pharmacies up for sale

The family-owned business has decided to sell all 34 pharmacies across the North of England

Whitworth Chemists Limited has instructed the property adviser, Christie & Co, to sell six of its pharmacies in Blackpool, as part of the company’s wider portfolio sale across the North of England.


The pharmacies are located on Kingscote Drive, Charles Street, Whitegate Drive, Bloomfield Road, Waterloo Road, and Common Edge Road.

According to the specialist broker, these are high-dispensing pharmacies, dispensing an average of circa 9,700 items per month.

Some of the accompanying freehold buildings are also up for sale, and interest is invited on a group, subgroup, or individual basis.

Jon Booth, Director – Pharmacy at Christie & Co, who is handling the sale, said: “We are delighted to have been engaged by the family and shareholders of Whitworth Chemists Limited in this exciting project.

“Rarely does a group of this size and quality come to market and be offered for sale on a group, subgroup, or individual pharmacy basis, and we expect significant interest to be generated for the pharmacies,” he added.

John Whitworth first started the pharmacy business in 1967 and, after stepping out of wholesaling, established a new pharmacy chain, Whitworth Chemists Limited in 1999, and since then, the chain remained family-owned.

In total, the family-owned chain has 34 community and health centre pharmacies located across the North of England - nine in Newcastle upon Tyne and Teesside, 10 in Yorkshire and the Humber, five in Greater Manchester and East Lancashire, and 10 in Blackpool and the West Coast.

Across the portfolio, the average dispensing volume is circa 8,500 items per month, with volumes ranging from 3,000 items to 22,000 items.

The decision to sell the business was taken following a strategic review by the family shareholders.

Jay Badenhorst, Managing Director at Whitworth Chemists Limited, and Superintendent Pharmacist, commented, “Whitworth Chemists Limited has built a strong business over the last three decades, delivering a range of quality pharmacy services to a wide patient group across the North of England.

“The business benefits from an amazing, dedicated team delivering first-class pharmacy services daily. However, the time has come for the family shareholders to step back from the business, thereby offering a great opportunity for a new purchaser or purchasers to continue to build on the enviable reputation we have created.”

With its support office in Scunthorpe, North Lincolnshire, the business has centralised services and MHRA-approved warehousing facilities which will also be available for sale, said the property adviser calling it “an opportunity which does not come on the market often.

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less